-
Ripretinib, REPODX, Repotrectinib
Regular price ¥2,700.00 CNYRegular priceUnit price per¥3,800.00 CNYSale price ¥2,700.00 CNYSale -
Ripretinib is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Regular price ¥2,400.00 CNYRegular priceUnit price per¥3,800.00 CNYSale price ¥2,400.00 CNYSale -
Ripretinib Laos Plant No. 2
Regular price ¥2,200.00 CNYRegular priceUnit price per -
Entrectinib, ENTREDX, Entrectinib 200mg
Regular price ¥1,900.00 CNYRegular priceUnit price per¥2,300.00 CNYSale price ¥1,900.00 CNYSale -
SalePHOENTRE Entrectinib
Regular price ¥1,200.00 CNYRegular priceUnit price per¥3,000.00 CNYSale price ¥1,200.00 CNYSale -
Aentrek ENTRECTINIB 200mg 90 'S Approval No. 02 L 0844/21 Expiry Date 21-8-2027
Regular price ¥3,300.00 CNYRegular priceUnit price per¥6,000.00 CNYSale price ¥3,300.00 CNYSale -
Aentrek ENTRECTINIB 100MG 30'S Approval No. 02 L 0844/21 Expiry Date 21-8-2027
Regular price ¥900.00 CNYRegular priceUnit price per¥2,000.00 CNYSale price ¥900.00 CNYSale -
Enrectinib is a specific tyrosine kinase inhibitor designed for the fusion of NTRK and ROS1 genes, used to treat NTRK fusion-positive locally advanced or metastatic solid tumors.
Regular price ¥1,275.00 CNYRegular priceUnit price per¥2,300.00 CNYSale price ¥1,275.00 CNYSale -
Entrectinib 200mg Entrectinib is a kinase inhibitor indicated for the treatment of: 1. Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
Regular price ¥3,100.00 CNYRegular priceUnit price per¥6,000.00 CNYSale price ¥3,100.00 CNYSold out
